Grupo Espanol De Tumores Neuroendocrinos

This Phase 3 trial tests whether a radioactive drug called 177Lu-edotreotide works better than the standard drug everolimus for people with advanced neuroendocrine tumors of the lung or thymus. About 170 participants will receive either six cycles of the radioactive therapy or da…

This study tests a drug called tarlatamab, which helps the immune system find and attack cancer cells. It is for people with advanced neuroendocrine carcinomas of the digestive system or unknown origin, a rare and aggressive cancer with limited treatment options. About 87 partici…

This study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…